BioSpace News Archive

Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.

Enveric Biosciences, Inc., a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, reported its financial results for the three months ended March 31, 2021.

Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777

Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences

OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m. ET.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Companys CEO, John Temperato will present a corporate update at Oppenheimers Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, announced that the Israel Innovation Authority selected Enlivex’s ongoing sepsis clinical program to receive a second non-dilutive grant of approximately $1.1 million for 2021.

Amolyt Pharma, a global pharmaceutical company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the 23 rd European Congress of Endocrinology (e-ECE) 2021 to be held virtually from May 22-26, 2021 as well as an abstract at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2021 to be held virtually

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of an inducement award to Dennis Kim, MD in connection with his appointment as the company’s Chief Medical Officer.

Fresenius Medical Care North America’s Renal Therapies Group introduces the Kinexus™ Therapy Management Platform, a new connected health platform for home dialysis that supports the management of a patient’s peritoneal dialysis therapy on the Liberty® Select cycler.